Exemplary performance data for immunosuppressants

Significance of the Topic

Accurate measurement of immunosuppressant drugs such as cyclosporin A, everolimus, sirolimus and tacrolimus is critical for patient management in transplantation and autoimmune therapy. Liquid chromatography tandem mass spectrometry (LC-MS/MS) offers high specificity, sensitivity and throughput required for reliable in vitro diagnostics in clinical laboratories.

Objectives and Study Overview

This study evaluates the analytical performance of the Thermo Scientific Vanquish MD HPLC coupled with the TSQ Quantis MD triple-stage quadrupole mass spectrometer across multiple instrument combinations. The aim is to demonstrate linearity, accuracy and precision for whole blood quantification of four key immunosuppressants under conditions suitable for laboratory-developed test workflows.

Methodology and Instrumentation Used

Sample Preparation

• Protein precipitation using zinc sulfate followed by transfer of supernatant to HPLC vials.

Chromatographic Conditions

• Mobile phase A: 0.1% formic acid and 10 mM ammonium formate in water.
• Mobile phase B: 0.1% formic acid and 10 mM ammonium formate in methanol.

Mass Spectrometry Settings

• Run time: 3 minutes per injection.
• Ionization: positive polarity heated electrospray ionization (HESI).
• Detection: selected reaction monitoring (SRM) transitions with quantifier and qualifier ions.

Instrumentation

• Vanquish MD HPLC system (Thermo Scientific) approved for in vitro diagnostic use.
• TSQ Quantis MD Series triple quadrupole mass spectrometer (Thermo Scientific).
• TraceFinder LDT software for data processing and quantitation.

Main Results and Discussion

Calibration and Linearity

• Six-point calibration curves for each analyte showed correlation coefficients (R²) above 0.997 across all instrument pairings.
• Deviation from assigned calibrator values remained below ±15%, meeting predefined acceptance criteria.

Precision and Accuracy

• Within-run and between-day precision studies (n=5 to n=35) yielded coefficients of variation (CV) below 7.8% at low, medium and high control levels.
• Recoveries of control samples were within ±15% of target values.

Chromatographic and Spectral Confirmation

• Clear baseline separation achieved within a 3-minute window for all four drugs.
• MS2 spectra displayed distinct quantifier and qualifier ion transitions, supporting compound confirmation.

Benefits and Practical Applications

The validated LC-MS/MS workflow enables fast, robust and reproducible measurement of immunosuppressants in clinical laboratories. High throughput and stringent in vitro diagnostic labeling ensure suitability for therapeutic drug monitoring, quality control and laboratory-developed assay implementation.

Future Trends and Potential Applications

Advances in software automation and artificial intelligence-driven method optimization are expected to further streamline LC-MS/MS assays. Expansion of quantitation panels to include additional metabolites and biomarkers will enhance patient monitoring capabilities. Integration with laboratory information systems and remote diagnostics may support decentralized testing models.

Conclusion

The combination of Vanquish MD HPLC and TSQ Quantis MD mass spectrometry delivers reliable performance for quantifying key immunosuppressants in whole blood. The method meets stringent accuracy and precision targets, providing a robust platform for clinical laboratories.

References

1. Clinical and Laboratory Standards Institute. Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline. CLSI document C62-A. Wayne, PA; 2014.